Erlotinib Effectively Inhibits JAK2V617F Activity and Polycythemia Vera Cell Growth
Open Access
- 1 February 2007
- journal article
- Published by Elsevier BV in Journal of Biological Chemistry
- Vol. 282 (6), 3428-3432
- https://doi.org/10.1074/jbc.c600277200
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- JAK2V617F: prevalence in a large Chinese hospital populationBlood, 2006
- The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disordersBlood, 2005
- Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR MutantsPLoS Medicine, 2005
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Identification of 1,2,3,4,5,6-Hexabromocyclohexane as a Small Molecule Inhibitor of Jak2 Tyrosine Kinase AutophophorylationJournal of Medicinal Chemistry, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitroBlood, 2003
- Imatinib mesylate (GleevecTM) reduces phlebotomy requirements in polycythemia veraLeukemia, 2003